Pure Global
NCT05829967

CIPN and it's Impact on Quality of Life in Patients Receiving Platinum and Taxanes

Chemotherapy Induced Peripheral Neuropathy (CIPN ) and it's Impact on Quality of Life in Patients Receiving Platinum and Taxanes at Assuit University Hospital
Assiut University·ClinicalTrials.govNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chemotherapy-induced Peripheral Neuropathy
Study type
Observational
Sponsor & location
Primary sponsor
Assiut University
Timeline & enrollment
Phase
N/A
Start date
Jun 01, 2023
End date
Aug 01, 2024
Enrollment
60 participants
Primary outcome

Number of patients with CIPN who receiving taxanes and platinum,Rae of recovery in patients with CIPN who receiving taxanes and platinum

Summary

Neuropathies are a major cause of moderate to severe impairments in cancer patients.
 
 Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects
 caused by antineoplastic agents, with a prevalence from 19% to over 85%.

ICD-10 classifications
Drug-induced polyneuropathyParaneoplastic neuromyopathy and neuropathyPolyneuropathy due to other toxic agentsIdiopathic peripheral autonomic neuropathyIdiopathic progressive neuropathy
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05829967
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05829967 through Pure Global AI's free database. This phase not specified trial is sponsored by Assiut University and is currently Not yet recruiting. The study focuses on Chemotherapy-induced Peripheral Neuropathy. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.